The Daily Toke

April 24, 2026

Acting Attorney General Todd Blanche signed an order Thursday that reclassified state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, marking the most significant federal shift in cannabis policy in over five decades. The move, which came roughly five months after President Trump signed an executive order directing the Justice Department to expedite the process, immediately places FDA-approved marijuana products and state-regulated medical cannabis in the same drug category as ketamine and Tylenol with codeine—a dramatic departure from the 1970 classification that grouped cannabis with heroin, LSD, and ecstasy. The administration also announced that beginning June 29, expedited administrative hearings will consider whether to broaden rescheduling to include recreational marijuana, setting the stage for potentially more sweeping changes.

💰 MONEY MOVES The reclassification delivers immediate financial relief to licensed medical marijuana operators. Schedule III status opens the door to federal tax breaks—specifically relief from Section 280E, which has long prevented cannabis businesses from deducting ordinary business expenses, a burden that doesn't apply to retailers of alcohol, tobacco, or pharmaceutical products. Medical marijuana licensees in states like Massachusetts and Arizona can expect significant tax savings, while research barriers ease considerably. Massachusetts Cannabis Control Commission Executive Director Travis Ahern stated the state is "looking forward to this change potentially providing benefits for medical marijuana licensees such as changes to federal tax status under 280E, new research opportunities, and improved support for patient access." Pennsylvania Gov. Josh Shapiro called the move an "important step" and signaled readiness to push lawmakers toward recreational legalization—a policy he's championed since 2019 and included in every budget proposal, projecting $729 million in annual tax revenue if enacted by July 1.

🚀 THIS IS COOL The reclassification removes a major obstacle to rigorous medical research that has existed for decades. Acting Attorney General Blanche noted that the changes "will enable more targeted, rigorous research into marijuana's safety and efficacy, expanding patients' access to treatments and empowering doctors to make better-informed healthcare decisions." For over 50 years, Schedule I status—defined as drugs with no accepted medical use and high abuse potential—has made it extremely difficult for researchers to study cannabis's therapeutic applications. Now, with medical marijuana in Schedule III, scientists can conduct more expansive trials on potential treatments for conditions ranging from chronic pain to PTSD, potentially transforming how the medical community understands and prescribes cannabis-based medicines.

However, the order reveals significant complications. The Trump administration's own Solicitor General John D. Sauer filed a Supreme Court brief Thursday arguing that the rescheduling should not impact a pending case (U.S. v. Hemani) challenging the federal ban on gun ownership for marijuana users. Sauer argued that because Hemani's marijuana use predates the rescheduling, it "remains a Schedule I controlled substance" under the retroactive application of law—meaning the Justice Department is simultaneously arguing that marijuana is too dangerous for gun owners while maintaining that rescheduling doesn't address that danger. Additionally, the bifurcation of cannabis into two schedules creates regulatory chaos: state-licensed medical operators move to Schedule III, while recreational dispensaries and unlicensed growers remain in Schedule I, leaving businesses holding dual licenses in a state of legal limbo and creating what Colorado cannabis attorney Rachel Gillette called "very odd" policy that "certainly is going to cause a lot of potential confusion and complications."

🤔 THINK ABOUT IT The federal government maintains that marijuana users pose a unique danger justifying firearm restrictions—a position it's defending even as it concedes medical benefits significant enough to warrant rescheduling and expanded research. Meanwhile, alcohol kills approximately 95,000 Americans annually, prescription opioids kill over 16,000 per year, and cannabis has never recorded a single overdose death in human history. State-level momentum continues regardless of federal posturing: 40 states now permit medical cannabis use, 24 states plus Washington D.C. have legalized recreational use, and a 2024 federal survey showed 22 percent of Americans age 12 and older used marijuana in the previous year—up from 19 percent in 2021, with 64 percent of Americans now supporting legalization according to Gallup. The June 29 hearing will determine whether the Trump administration pursues full rescheduling or leaves the cannabis market permanently split between medical and recreational tiers.

April 24, 2026

Federal reclassification of cannabis just shifted the entire landscape of the American cannabis business. The Trump administration moved Thursday to downgrade cannabis from Schedule I to Schedule III under the DEA's controlled substances framework—a landmark policy reversal that marks one of the most significant federal shifts on marijuana policy in decades. Schedule I drugs like heroin and LSD are considered to have no accepted medical use and high abuse potential. Schedule III drugs like Tylenol with codeine, by contrast, are recognized as having legitimate medical applications and face fewer regulatory restrictions. The Department of Justice said it will immediately move FDA-approved cannabis products and items regulated under state medical marijuana licenses to Schedule III, with an expedited hearing scheduled for June to consider formal reclassification.

💰 MONEY MOVES The financial implications are staggering. Cannabis companies will be exempt from IRS Code Section 280E for the first time, allowing them to deduct standard business expenses like rent and payroll—a massive tax benefit that could reshape company profitability across the industry. The reclassification also opens the door to banking access that was previously barred, a fundamental barrier that has forced cannabis operators to operate largely in cash for decades. Tilray CEO Irwin Simon told CNBC he expects a wave of pharmaceutical partnership inquiries similar to what the hemp industry saw with alcohol companies, signaling that major corporate players are now ready to enter the space legally. "We have the research to walk into the FDA and the DEA and show them what we've been doing," Simon said, indicating that companies have been preparing for this regulatory shift for years.

The move comes as Florida's medical cannabis market—the largest in the U.S. at roughly $1 billion annually—has become a battleground state where companies like Trulieve, Curaleaf, and Surterra are locked in aggressive pricing wars for market dominance. Trulieve controls about 50% of Florida's market, but competitors are undercutting prices dramatically, with dispensaries offering 30% off flower and 25% off concentrates daily. The state's limited licensing structure and vertical integration requirements make it one of the most competitive cannabis markets in the country, second only to California and Colorado in annual sales. 🚀 THIS IS COOL Reclassification removes longstanding barriers that have made it nearly impossible for researchers to conduct clinical studies on cannabis, potentially unlocking scientific understanding of cannabinoids like CBD and CBG that have shown promise for treating chronic pain, seizures, nausea, and anxiety.

However, investor skepticism tempered early enthusiasm. Cannabis stocks initially surged on the reclassification news but pulled back and turned negative as traders digested potential complications. Critics worry that the policy could create a two-track system for drug development, allowing some developers to bypass the FDA process entirely in favor of state-level regulatory pathways—a scenario that could fragment the market and create safety inconsistencies. For Canadian cannabis companies like Aurora Cannabis, which have been barred from the U.S. market, the news offers limited immediate relief; Aurora's stock has declined over 99% since 2019, falling from $900 per share to around $6 today due to massive cash burn and shareholder dilution. 🤔 THINK ABOUT IT The federal government has classified cannabis as having no medical use since 1970—for over 50 years—while simultaneously approving FDA medications containing cannabidiol and allowing 38 states to operate legal medical cannabis programs. What does Schedule I classification actually protect when the science has already moved forward?

April 24, 2026

Federal lawmakers are moving aggressively to crack down on hemp-derived THC products, launching what amounts to a coordinated effort to close what they call a regulatory "loophole" that has allowed a $28 billion industry to flourish largely unchecked. Congress is pushing hemp restrictions following pressure from state governments and the marijuana industry itself—a fact worth noting, since legal cannabis operators in states like Colorado and California have watched hemp-derived delta-8 and delta-10 THC products undercut their regulated market with cheaper, less-regulated alternatives. The crackdown reflects a genuine tension in cannabis policy: as traditional marijuana legalization spreads state-by-state, the federal government's continued Schedule I classification of cannabis has created a strange legal corridor where hemp-derived THC products exist in a gray zone, technically legal under the 2018 Farm Bill but increasingly controversial.

💰 MONEY MOVES The scale of what's at stake is enormous. Congressional restrictions on hemp-derived THC threaten a $28 billion industry and are already sending companies scrambling to understand what a federal ban would mean for their supply chains, retail operations, and customer base. States like Texas are already moving independently, launching their own crackdowns on THC flower sales—evidence that the pressure isn't just coming from Washington, but from state capitals facing questions about regulatory coherence. When you have legal cannabis businesses in regulated markets competing against unregulated hemp-derived products with lower compliance costs and lower prices, the math becomes clear: regulated operators see federal hemp restrictions as a way to restore what they call "pricing power" and market order.

What's less clear is whether a federal hemp ban actually solves the underlying problem, or simply shifts it. The federal government is attempting to close a loophole created by its own classification system—a Schedule I designation that has remained in place for over 50 years despite documented evidence that cannabis has zero recorded overdose deaths in human history, while alcohol kills approximately 95,000 Americans annually and prescription opioids kill 16,000 or more per year. 🤔 THINK ABOUT IT If child safety and public health are genuinely the driver of these restrictions, why is the federal government targeting a zero-death product while those more harmful legal substances remain unrestricted and widely available?

The practical consequences of a hemp ban extend beyond market dynamics. Veterans who rely on legal THC products for PTSD, chronic pain, and anxiety treatment face the real prospect of reduced access to regulated alternatives. When federal restrictions eliminate hemp-derived options without expanding legal pathways through traditional cannabis legalization, patients and veterans don't stop using THC—they shift to unregulated markets where product quality, dosing accuracy, and safety testing disappear entirely. South Carolina and other states are considering state-level bans on hemp-derived products, which could effectively end the industry in those jurisdictions and force consumers toward black market alternatives with zero regulatory oversight.

The timeline matters here. These congressional restrictions are being pursued in late 2025, the same moment when multiple states have either legalized cannabis or are actively considering it. The federal government is moving to restrict a product category that emerged precisely because full cannabis legalization hasn't happened—hemp-derived THC exists because Schedule I prevents normal cannabis from being sold legally in most states. Closing the hemp loophole without simultaneously rescheduling cannabis simply narrows consumer options without addressing the fundamental legal contradiction that created the loophole in the first place. Whether Congress intends to pair hemp restrictions with cannabis rescheduling remains to be seen; the articles suggest the restrictions are being pursued independently, which would mean eliminating a legal product category without offering regulated alternatives.

April 24, 2026

# THC in Science: Clinical Trials Begin as Evidence Gap Widens

Researchers at UCHealth and institutions across the country are launching comprehensive clinical trials to answer a question that's haunted cannabis policy for decades: does marijuana actually work as medicine? The timing is significant. While cannabis remains federally classified as Schedule I—a designation originally imposed despite a 1972 government commission recommending decriminalization—the scientific community is finally getting institutional backing to run rigorous studies on what patients have been reporting anecdotally for years. 🚀 THIS IS COOL These trials represent a potential turning point in how we understand cannabis's role in modern medicine, moving beyond assumption into measurable outcomes.

The evidence so far tells a mixed story. A major review published in December 2025 found that while cannabis shows genuine promise for chronic pain management, the scientific evidence supporting its use in most other conditions remains thin or absent. Science Daily reported that cannabis does appear to have meaningful effects on chronic pain—one of the most common reasons patients seek it out—yet researchers simultaneously revealed hidden risks that deserve attention: cognitive impacts, dependency potential, and complications in vulnerable populations. In other words, the plant isn't a miracle cure, but it isn't inert either. 🤔 THINK ABOUT IT We're discovering that cannabis has both real benefits and real tradeoffs—which is how most medicines actually work, yet somehow this balanced view took decades to appear in mainstream science.

The federal reclassification announced in December 2025 could accelerate research momentum significantly. 💰 MONEY MOVES Trump's move to reclassify THC and CBD has immediate implications for seniors seeking pain relief alternatives, for the research institutions that can now access funding and test subjects more easily, and for the stock market, where cannabis-adjacent companies began pricing in expanded market access. The reclassification doesn't legalize cannabis outright—Schedule III still carries restrictions—but it signals that the federal government is finally acknowledging what researchers have known: the current classification was never based on science. For over fifty years, Schedule I designation has made it nearly impossible to run the clinical trials that might have answered these questions decades ago.

The research gap is especially consequential for veterans. Thousands use legal THC products to manage PTSD, chronic pain, and anxiety—conditions that don't always respond well to pharmaceutical alternatives. When states or institutions restrict access based on old prohibition narratives, these patients face a narrowing window of care options. The studies now underway will provide the evidence base that patients and doctors desperately need to make informed decisions, rather than relying on policy frameworks built during the Nixon era and maintained through inertia.

What emerges from this convergence—new clinical trials, emerging evidence of real benefits, documented risks that are manageable, and a federal reclassification finally acknowledging the science—is a clearer picture: cannabis is a plant with genuine therapeutic applications in specific conditions, particularly chronic pain, and it comes with tradeoffs that deserve investigation and transparency. That's not advocacy. That's how medicine works. The question now is whether the research institutions will move quickly enough to answer what patients and doctors have been asking for decades.

April 24, 2026

Federal marijuana rescheduling is moving forward under the Trump administration, with Acting Attorney General Todd Blanche announcing that state-licensed medical cannabis products will immediately shift to Schedule III classification, while broader rescheduling enters an expedited administrative hearing process beginning June 29. The announcement fulfills an executive order the president issued more than four months ago, directing the Department of Justice to complete the rescheduling "in the most expeditious manner." Simultaneously, President Trump is pushing Congress to preserve access to full-spectrum CBD products ahead of November's scheduled federal recriminalization of hemp derivatives containing more than 0.4 milligrams of total THC per container—a threshold so restrictive that industry advocates warn it will eliminate popular therapeutic products currently used by roughly one in five American adults.

The contradictions within federal cannabis policy are becoming harder to ignore. Trump's administration is simultaneously moving to reschedule marijuana while urging Congress to carve out exceptions for hemp-derived CBD products, citing therapeutic value and agricultural benefits. 🚀 THIS IS COOL The administration also launched a new Medicare coverage program this month that will provide up to $500 annually in hemp-derived CBD and THC products for eligible seniors—a policy decision that implicitly acknowledges the medical legitimacy of products the federal government still classifies as Schedule I or II contraband. Trump's Truth Social post emphasized that CBD "has made a HUGE difference for so many people" and noted that hemp-derived products would "help our GREAT FARMERS," signaling political alignment with both patient advocacy and agricultural interests.

Meanwhile, Congress is laying groundwork for potentially more comprehensive oversight. The House Appropriations Committee approved spending legislation this week that directs the Treasury Department's Alcohol and Tobacco Tax and Trade Bureau to coordinate an assessment of state marijuana regulatory frameworks across the 20+ states permitting adult use and 35+ states permitting medical cannabis. The directive also asks the Department of Justice to assess methods for preventing diversion of legally produced cannabis into prohibition states—a pragmatic acknowledgment that legal markets in neighboring jurisdictions create enforcement challenges for states maintaining prohibition. The committee has approved similar provisions in past years, though it remains unclear whether the TTB has consistently filed resulting policy reports with lawmakers.

The rescheduling announcement has drawn mixed reactions from lawmakers and advocates, with many calling it overdue while others argue it doesn't go far enough. 🤔 THINK ABOUT IT Over 50 years have passed since the Controlled Substances Act placed cannabis in Schedule I despite the Nixon administration's own Shafer Commission recommending decriminalization—and during those decades, the federal classification remained unchanged despite alcohol causing approximately 95,000 deaths annually in the United States and prescription opioids claiming over 16,000 lives per year, while cannabis has never produced a single recorded overdose death in human history. The Trump administration's gun rights argument—asserting that federal rescheduling should not impact Supreme Court cases deciding whether cannabis users can legally purchase firearms—further illustrates the fractured nature of current cannabis policy, where the plant simultaneously moves toward medical legitimacy while remaining entangled with felony consequences in certain contexts.

💰 MONEY MOVES The policy shifts signal substantial market implications. Immediate Schedule III classification for state-licensed medical products will reduce regulatory burden for the estimated hundreds of millions in annual sales across licensed dispensaries, while the Medicare coverage program creates a new reimbursement pathway that could reshape how seniors access hemp products. The hemp recriminalization deadline looming in November—currently set to eliminate most full-spectrum CBD products—has created urgency in congressional negotiations, with Republican lawmakers including Reps. James Comer and Andy Barr filing Farm Bill amendments to delay recriminalization and establish continued legal sales frameworks. The window for congressional action is narrow, and the administration's public support provides political cover for lawmakers voting to preserve access to products millions of Americans already use for chronic pain management and other therapeutic purposes.